Newron Pharmaceuticals S.p.A.

SWX:NWRN Stock Report

Market Cap: CHF 164.5m

Newron Pharmaceuticals Valuation

Is NWRN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NWRN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
CHF 49.40
Fair Value
83.3% undervalued intrinsic discount
3
Number of Analysts

Below Fair Value: NWRN (CHF8.24) is trading below our estimate of fair value (CHF49.4)

Significantly Below Fair Value: NWRN is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for NWRN?

Key metric: As NWRN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NWRN. This is calculated by dividing NWRN's market cap by their current earnings.
What is NWRN's PE Ratio?
PE Ratio11.1x
Earnings€15.84m
Market Cap€175.89m

Price to Earnings Ratio vs Peers

How does NWRN's PE Ratio compare to its peers?

The above table shows the PE ratio for NWRN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average42.6x
COPN Cosmo Pharmaceuticals
6.5x-51.1%CHF 805.6m
DESN Dottikon ES Holding
37.2xn/aCHF 2.8b
XLS Xlife Sciences
3.4xn/aCHF 117.7m
GALD Galderma Group
123.4x31.4%CHF 23.7b
NWRN Newron Pharmaceuticals
11.1x42.2%CHF 164.5m

Price-To-Earnings vs Peers: NWRN is good value based on its Price-To-Earnings Ratio (11.1x) compared to the peer average (42.6x).


Price to Earnings Ratio vs Industry

How does NWRN's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
NWRN 11.1xIndustry Avg. 22.2xNo. of Companies10PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: NWRN is good value based on its Price-To-Earnings Ratio (11.1x) compared to the European Pharmaceuticals industry average (21.2x).


Price to Earnings Ratio vs Fair Ratio

What is NWRN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NWRN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio11.1x
Fair PE Ratio26.8x

Price-To-Earnings vs Fair Ratio: NWRN is good value based on its Price-To-Earnings Ratio (11.1x) compared to the estimated Fair Price-To-Earnings Ratio (26.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NWRN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 8.24
CHF 17.62
+113.8%
27.8%CHF 22.97CHF 11.12n/a3
May ’26CHF 7.16
CHF 17.62
+146.1%
27.8%CHF 22.97CHF 11.12n/a3
Apr ’26CHF 7.55
CHF 15.80
+109.2%
19.8%CHF 18.75CHF 11.48n/a3
Mar ’26CHF 9.90
CHF 15.64
+58.0%
19.1%CHF 18.49CHF 11.51n/a3
Feb ’26CHF 9.46
CHF 15.64
+65.4%
19.1%CHF 18.49CHF 11.51n/a3
Jan ’26CHF 8.95
CHF 14.39
+60.7%
12.4%CHF 16.86CHF 12.70n/a3
Dec ’25CHF 7.74
CHF 14.42
+86.3%
12.6%CHF 16.94CHF 12.76n/a3
Nov ’25CHF 8.20
CHF 14.42
+75.8%
12.6%CHF 16.94CHF 12.76n/a3
Oct ’25CHF 7.70
CHF 14.42
+87.2%
12.6%CHF 16.94CHF 12.76n/a3
Sep ’25CHF 8.50
CHF 14.30
+68.2%
15.2%CHF 17.31CHF 12.23n/a3
Aug ’25CHF 8.48
CHF 14.30
+68.6%
15.2%CHF 17.31CHF 12.23n/a3
Jul ’25CHF 8.84
CHF 14.30
+61.8%
15.2%CHF 17.31CHF 12.23n/a3
Jun ’25CHF 10.00
CHF 14.45
+44.5%
14.3%CHF 17.29CHF 12.46n/a3
May ’25CHF 8.21
CHF 14.54
+77.2%
14.0%CHF 17.32CHF 12.48CHF 7.163
Apr ’25CHF 7.76
CHF 12.99
+67.4%
4.5%CHF 13.81CHF 12.45CHF 7.553
Mar ’25CHF 8.38
CHF 11.34
+35.3%
22.7%CHF 13.60CHF 7.74CHF 9.903
Feb ’25CHF 7.76
CHF 9.15
+17.9%
26.7%CHF 12.59CHF 7.18CHF 9.463
Jan ’25CHF 4.95
CHF 7.39
+49.3%
3.5%CHF 7.65CHF 7.13CHF 8.952
Dec ’24CHF 4.80
CHF 7.39
+54.0%
3.5%CHF 7.65CHF 7.13CHF 7.742
Nov ’24CHF 4.80
CHF 7.39
+54.0%
3.5%CHF 7.65CHF 7.13CHF 8.202
Oct ’24CHF 5.46
CHF 9.34
+71.1%
29.0%CHF 13.16CHF 7.19CHF 7.703
Sep ’24CHF 5.32
CHF 9.34
+75.6%
29.0%CHF 13.16CHF 7.19CHF 8.503
Aug ’24CHF 5.20
CHF 10.44
+100.8%
30.8%CHF 13.65CHF 7.23CHF 8.482
Jul ’24CHF 6.12
CHF 10.44
+70.6%
30.8%CHF 13.65CHF 7.23CHF 8.842
Jun ’24CHF 3.89
CHF 10.44
+168.4%
30.8%CHF 13.65CHF 7.23CHF 10.002
May ’24CHF 4.44
CHF 10.44
+135.1%
30.8%CHF 13.65CHF 7.23CHF 8.212
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
CHF 17.62
Fair Value
53.2% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/09 23:08
End of Day Share Price 2025/05/09 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Newron Pharmaceuticals S.p.A. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas MeyerBaader Helvea Equity Research
Bob PoolerBank am Bellevue
Maria MaldonadoBank Vontobel AG